Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Revenue (2020 - 2025)

Vivos Therapeutics' Revenue history spans 6 years, with the latest figure at $3.8 million for Q4 2025.

  • Quarterly results put Revenue at $3.8 million for Q4 2025, up 3.41% from a year ago — trailing twelve months through Dec 2025 was $17.4 million (up 16.05% YoY), and the annual figure for FY2025 was $17.4 million, up 16.05%.
  • Revenue for Q4 2025 was $3.8 million at Vivos Therapeutics, down from $6.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $6.8 million in Q3 2025 to a low of $3.0 million in Q1 2025.
  • The 5-year median for Revenue is $3.8 million (2023), against an average of $4.0 million.
  • The sharpest move saw Revenue fell 22.26% in 2023, then skyrocketed 75.73% in 2025.
  • Year by year, Revenue stood at $4.4 million in 2021, then decreased by 10.1% to $4.0 million in 2022, then decreased by 17.77% to $3.2 million in 2023, then grew by 13.85% to $3.7 million in 2024, then rose by 3.41% to $3.8 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $3.8 million, $6.8 million, and $3.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.